tetano
Editor, Senior Moderator
J Korean Med Sci
. 2022 Jul 4;37(26):e204.
doi: 10.3346/jkms.2022.37.e204.
A Case Report of MPO-ANCA-Associated Vasculitis Following Heterologous mRNA1273 COVID-19 Booster Vaccination
Beop Chang Kim[SUP] 1 [/SUP], Han Seong Kim[SUP] 2 [/SUP], Kum Hyun Han[SUP] 1 [/SUP], Sang Youb Han[SUP] 1 [/SUP], Hyung Ah Jo[SUP] 3 [/SUP]
Affiliations
Abstract
Despite that clinical trials have been examining the safety profile of coronavirus disease 2019 (COVID-19) vaccines, there are concerns about long-term side effects as the number of vaccinations increases. Herein, we report a case of new-onset renal-limited anti-myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis after booster vaccination with the mRNA 1273 (Moderna) vaccine. A 72-year-old woman with no specific past history, and who had a normal renal function, developed ANCA-associated vasculitis following heterologous booster with mRNA1273 (Moderna) vaccine. After a kidney biopsy, she was diagnosed with ANCA-associated pauci-immune crescentic glomerulonephritis. Her renal function and constitutional symptoms have been improved with treatment with plasmapheresis, intravenous cyclophosphamide and steroid pulse therapy (intravenous 500 mg of methylprednisolone sodium succinate for 3 days) followed by a reduced steroid regimen.
Keywords: ANCA-Vasculitis; Heterologous; mRNA1273 COVID-19 Vaccine.
. 2022 Jul 4;37(26):e204.
doi: 10.3346/jkms.2022.37.e204.
A Case Report of MPO-ANCA-Associated Vasculitis Following Heterologous mRNA1273 COVID-19 Booster Vaccination
Beop Chang Kim[SUP] 1 [/SUP], Han Seong Kim[SUP] 2 [/SUP], Kum Hyun Han[SUP] 1 [/SUP], Sang Youb Han[SUP] 1 [/SUP], Hyung Ah Jo[SUP] 3 [/SUP]
Affiliations
- PMID: 35790206
- DOI: 10.3346/jkms.2022.37.e204
Abstract
Despite that clinical trials have been examining the safety profile of coronavirus disease 2019 (COVID-19) vaccines, there are concerns about long-term side effects as the number of vaccinations increases. Herein, we report a case of new-onset renal-limited anti-myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis after booster vaccination with the mRNA 1273 (Moderna) vaccine. A 72-year-old woman with no specific past history, and who had a normal renal function, developed ANCA-associated vasculitis following heterologous booster with mRNA1273 (Moderna) vaccine. After a kidney biopsy, she was diagnosed with ANCA-associated pauci-immune crescentic glomerulonephritis. Her renal function and constitutional symptoms have been improved with treatment with plasmapheresis, intravenous cyclophosphamide and steroid pulse therapy (intravenous 500 mg of methylprednisolone sodium succinate for 3 days) followed by a reduced steroid regimen.
Keywords: ANCA-Vasculitis; Heterologous; mRNA1273 COVID-19 Vaccine.